The clinically approved antiviral drug sofosbuvir inhibits Zika virus replicationCarolina Q. Sacramento, Thiago Moreno L. Souza, Mônica M. Bastos et al.|Scientific Reports|2017Cited by 243
Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivoCaroline S. de Freitas, Thiago Moreno L. Souza, Luiza M. Higa et al.|PLoS neglected tropical diseases|2019Cited by 124
<i>In vitro</i> antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19Carolina Q. Sacramento, Thiago Moreno L. Souza, Natalia Fintelman‐Rodrigues et al.|Journal of Antimicrobial Chemotherapy|2021Cited by 104
Beyond Members of the <i>Flaviviridae</i> Family, Sofosbuvir Also Inhibits Chikungunya Virus ReplicationAndré C. Ferreira, Thiago Moreno L. Souza, Patrícia A. Reis et al.|Antimicrobial Agents and Chemotherapy|2018Cited by 98
The <i>in vitro</i> antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2Carolina Q. Sacramento, Thiago Moreno L. Souza, Natalia Fintelman‐Rodrigues et al.|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 37